IVVD Quote, Financials, Valuation and Earnings

Amneal Pharmaceuticals has a net margin of -144.1% compared to Invivyd's net margin of 1.75%. Invivyd's return on equity of -136.18% beat Amneal Pharmaceuticals's return on equity of -587.3%.

Invivyd has a consensus price target of $6.60, signalling upside risk potential of 633.9%. On the other hand Amneal Pharmaceuticals has an analysts' consensus of $11.67 which suggests that it could grow by 60.04%. Given that Invivyd has higher upside potential than Amneal Pharmaceuticals, analysts believe Invivyd is more attractive than Amneal Pharmaceuticals.

Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amneal Pharmaceuticals has a beta of 1.171, suggesting its more volatile than the S&P 500 by 17.079%.

Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. Amneal Pharmaceuticals pays out -- of its earnings as a dividend.

Invivyd quarterly revenues are $11.3M, which are smaller than Amneal Pharmaceuticals quarterly revenues of $695.4M. Invivyd's net income of -$16.3M is lower than Amneal Pharmaceuticals's net income of $12.2M. Notably, Invivyd's price-to-earnings ratio is -- while Amneal Pharmaceuticals's PE ratio is 101.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is 2.93x versus 0.81x for Amneal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PepGen has a net margin of -144.1% compared to Invivyd's net margin of --. Invivyd's return on equity of -136.18% beat PepGen's return on equity of --.

Invivyd has a consensus price target of $6.60, signalling upside risk potential of 633.9%. On the other hand PepGen has an analysts' consensus of $11.80 which suggests that it could grow by 689.12%. Given that PepGen has higher upside potential than Invivyd, analysts believe PepGen is more attractive than Invivyd.

Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PepGen has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PepGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. PepGen pays out -- of its earnings as a dividend.

Invivyd quarterly revenues are $11.3M, which are larger than PepGen quarterly revenues of --. Invivyd's net income of -$16.3M is higher than PepGen's net income of -$30.2M. Notably, Invivyd's price-to-earnings ratio is -- while PepGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is 2.93x versus -- for PepGen. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -144.1% compared to Invivyd's net margin of 21.63%. Invivyd's return on equity of -136.18% beat Pfizer's return on equity of 8.72%.

Invivyd has a consensus price target of $6.60, signalling upside risk potential of 633.9%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 24.95%. Given that Invivyd has higher upside potential than Pfizer, analysts believe Invivyd is more attractive than Pfizer.

Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.2% to investors and pays a quarterly dividend of $0.43 per share. Invivyd pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Invivyd quarterly revenues are $11.3M, which are smaller than Pfizer quarterly revenues of $13.7B. Invivyd's net income of -$16.3M is lower than Pfizer's net income of $3B. Notably, Invivyd's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is 2.93x versus 2.16x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Entrada Therapeutics has a net margin of -144.1% compared to Invivyd's net margin of -84.39%. Invivyd's return on equity of -136.18% beat Entrada Therapeutics's return on equity of 6.3%.

Invivyd has a consensus price target of $6.60, signalling upside risk potential of 633.9%. On the other hand Entrada Therapeutics has an analysts' consensus of $23.67 which suggests that it could grow by 207.36%. Given that Invivyd has higher upside potential than Entrada Therapeutics, analysts believe Invivyd is more attractive than Entrada Therapeutics.

Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

Invivyd quarterly revenues are $11.3M, which are smaller than Entrada Therapeutics quarterly revenues of $20.6M. Invivyd's net income of -$16.3M is higher than Entrada Therapeutics's net income of -$17.3M. Notably, Invivyd's price-to-earnings ratio is -- while Entrada Therapeutics's PE ratio is 9.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is 2.93x versus 1.79x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.